Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2018-10-24 Report Publication Anno…
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
Correction: ViroGates releases third quarter 2018 results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding the release of the company's third-quarter 2018 financial results. It provides a summary of highlights and explicitly includes a link to the full report as an 'Attachment'. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the interim report itself.
2018-10-24 English
ViroGates releases third quarter 2018 results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for ViroGates A/S covering the third quarter of 2018. It includes detailed financial statements (Income Statement, Cash Flow, Equity), operational reviews, and business highlights. It is not merely an announcement or a short summary, but a substantive interim report containing actual financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2018
2018-10-24 English
ViroGates releases third quarter 2018 results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) titled 'ViroGates releases third quarter 2018 results'. It provides a summary of financial and business highlights and explicitly includes an 'Attachment' section with a link to the full 'Interim Financial Report Q3 2018'. According to the 'Menu vs Meal' rule, since this is a short announcement of a report that is attached/linked, it is classified as a Report Publication Announcement (RPA).
2018-10-24 English
ViroGates Announces Its First International Clinical Customer
Regulatory Filings Classification · 90% confidence The document is a company announcement regarding a new clinical customer agreement for ViroGates. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2018-07-31 English
ViroGates Announces Its First International Clinical Customer
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a new clinical customer agreement. It does not fit into specific financial reporting categories like 10-K, IR, or ER. Since it is a general corporate announcement released via a regulatory channel (Nasdaq First North) and does not fall into the other specialized categories, it is classified as a general regulatory filing.
2018-07-31 English
ViroGates Releases Second Quarter 2018 Financial Results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for ViroGates A/S covering the second quarter (Q2) and the first half (H1) of 2018. It includes detailed financial statements (Income Statement, Balance Sheet, Cash Flow Statement), notes to the accounts, and management's operational review. It is not a short announcement, but a full interim report containing substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). Q2 2018
2018-07-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.